Lignes directrices sur la prévention de l’alloimmunisation fœto-maternelle Rh

Prévention de l’alloimmunisation fœto-maternelle Rh prénatale et en période post-partum – Revue systématique et évaluation GRADE

Statut du projet: Terminé

Utilisateur(s) des connaissances

Société des obstétriciens et gynécologues du Canada

Project Trainee(s)

Alan Michaud, Leila Esmaeilisaraji, Lindsey Sikora

Collaborator(s)

Karen Fung-Kee-Fung

Source(s) de financement

Instituts de recherche en santé du Canada (IRSC), dans le cadre de l’Alliance pour des données probantes de la Stratégie de recherche axée sur le patient (SRAP), Canadian Institutes of Health Research (CIHR) through the Strategy for Patient-Oriented Research (SPOR) Evidence Alliance

Objectif du projet

À l’aide du cadre GRADE (Grading of Recommendations Assessment, Development and Evaluation), résumer et évaluer la certitude des données probantes issues des essais contrôlés randomisés et des études observationnelles comparatives sur l’efficacité préventive de l’immunoglobuline anti-D chez les personnes enceintes ou en période post-partum Rh négatives présentant un risque d’alloimmunisation.

Approche de recherche

Revue systématique, GRADE Analysis

Responsables du projet

Brian Hutton

Position: Ottawa Hospital Research Institute, University of Ottawa
Email: bhutton@ohri.ca

Dr. Hutton is a Senior Scientist with the OHRI’s Clinical Epidemiology Program, an Associate Professor within the University of Ottawa’s Faculty of Epidemiology and Community Medicine and Adjunct Scientist with the Royal Ottawa Mental Health Center. His primary research interests currently lie in the realm of network meta-analysis, systematic reviews and other forms of evidence synthesis. He directed the Knowledge Synthesis Group from 2015-22, and previously led CIHR-funded network meta-analysis research projects and other forms of knowledge synthesis (including systematic reviews, rapid reviews and scoping reviews) for the Drug Safety and Effectiveness Network, with topics including treatments for latent tuberculosis, the influence of industry relationships on prescribing, the incidence of preventable adverse drug reactions, and best evidence interventions for management of chronic pain, amongst others. Dr. Hutton was awarded a 5-year CIHR New Investigator Award and led the development of the extension of the PRISMA statement for reporting of network meta-analyses. Dr. Hutton also contributes time to the Ottawa Regional Cancer Center in the role of methodologist. His past and current research includes works in the realms of oncology, transfusion medicine, infectious diseases, mental health, addiction medicine and several other clinical fields. Most recently Dr. Hutton has undertaken research related the evaluation of interventions for opioid use disorder, the health effects of cannabis consumption and artificial intelligence applications in knowledge synthesis. He holds an H-index of 69, an I10-index of 222 and has been awarded many grants as PI, co-PI and co-I.

Research Interests: Systematic reviews and meta-analysis; network meta-analysis (and other methods for indirect comparisons of interventions); technology assessment; rapid reviews; scoping reviews; overviews; oncology; mental health and addiction; real-world data.

Brian Hutton

Ottawa Hospital Research Institute, University of Ottawa

Dr. Hutton is a Senior Scientist with the OHRI’s Clinical…